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der commercial plans and PDP for 2 high-use drugs in each of the six therapeutic
classes deemedmedically necessary by CMS for beneficiaries aswell as two statins,
for reference. METHODS: TRx and OPC were collected annually from 2002 to 2009
for the two most prescribed drugs in the six medically necessary classes: anticon-
vulsants, antidepressants, oral antineoplastics, antipsychotics, immunosuppres-
sants, and HIV/AIDS—plus statins (14 drugs total). Data are from SDI’s VONA and
VOPA, analyzed with 2-way ANOVA; significance at p0.05. RESULTS: All drugs
analyzed had annual increases of10% per year in PDP prescription volume. How-
ever, nine drugs had significantly greater annual increases in commercial plan
prescription volumes before PDP than after, compared to only one with signifi-
cantly greater increases after PDP. Six drugs had significantly greater increases in
overall prescription volume after PDP compared to before. Five drugs had annual
OPC increases of at10% per year in PDP compared to two that posted at least 10%
annual decreases. Six drugs had significantly greater annual OPC increases before
PDP compared to after under commercial plans; only one had greater increases
after Part D compared to before. Five drugs showed significantly greater increases
in overall OPC (all payment forms averaged) before PDP compared to after.
CONCLUSIONS: In commercial drug plans, the advent of Part D correlates with
slower increases in drug utilization. However, Part D utilization has increased sig-
nificantly for all drugs, indicating a greater shift toward Part D plans. That only five
drugs under Part D increased in OPC bymore than 10% (and two decreased overall)
suggests that this shift may be due to greater patient access.
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NUMBER AND TYPE OF DRUGS USED BY SENIORS ON PUBLIC DRUG PROGRAMS
IN CANADA, 2002 TO 2008
Hunt J, Gaucher M
Canadian Institute for Health Information, Ottawa, ON, Canada
OBJECTIVES: The use of multiple medications can increase the risk of adverse
effects, drug interactions and non-compliance with drug therapy, all of whichmay
result in less-than-optimal health outcomes. Seniors are at a particularly high risk
of adverse effects. Although it may be appropriate for a patient to be taking a high
number of medications, the additional risks should be considered. This analysis
examines the number and types of drugs being used by seniors, andhowutilization
changes as seniors age. METHODS: Claims level data from the National Prescrip-
tion Drug Utilization Information System (NPDUIS) Database were analyzed for
1,039,642 seniors on public drug programs in six Canadian provinces between 2002
and 2008, representing over 80% of the senior population in those provinces in
2008. Drug classes were defined using theWorld Health Organization’s Anatomical
Therapeutic Chemical classifications. The number of drugs was calculated as the
number of unique drug classes a person claimed in a given year. RESULTS: In 2008,
21.4% of seniors on public drug programs had claims for 10 or more drug classes, a
slight increase from 2002 (18.6%). The number of drug classes used by seniors
increased with age. The most commonly used drug classes were used to treat
chronic conditions such as high cholesterol, high blood pressure, heart failure, and
emphysema. 3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase inhibitors were
the most commonly used drug class among seniors aged 65 to 84, while single-
ingredient angiotensin-converting enzyme inhibitors were the most commonly
used class among those aged 85 and over. CONCLUSIONS: Findings suggest a high
proportion of seniors may be at risk for drug interactions and other adverse events
due to the number of medications they are taking. This illustrates the importance
ofmedicationmanagement strategies for seniors, and the need for communication
between health care providers regarding seniors’ drug regimens.
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THE POTENTIAL VALUE OF THE 2014 MEDICAID EXPANSION
Sepulveda B, Doyle J
Quintiles, Hawthorne, NY, USA
OBJECTIVES:With the imminent $40 billion expansion of Medicaid in 2014, health
insurers face new opportunities to benefit by privately managing these growing
plans for some of the larger states. Overall, the States will see a 32% increase—
approximately 16 million— in Medicaid enrollees in 2014 (UnitedHealth). We ana-
lyzed the potential windfall of this expansion in the ten states with the largest
projected growth in five of the largest drug markets. METHODS: Prescription vol-
ume (TRx) and out-of-pocket costs (OPC) in five of the largest drugmarkets (depres-
sion, diabetes, hypertension, cholesterol, pain) were obtained for the ten states
with the largest Medicaid enrollment increases (California, Texas, Florida, Penn-
sylvania, Ohio, Michigan, Georgia, North Carolina, Illinois, Louisiana; Source: Unit-
edHealth). Data were obtained from June 2006 to June 2010; SDI VONA and VOPA
databases. RESULTS:Medicaid prescriptions represent a significant portion of TRx
in the 10 states analyzed, from 2.7% (MI) to 8.9% (IL). Furthermore, Medicaid ac-
counts for a considerable fraction of TRx in each of the drug markets analyzed,
from 1.5% (cholesterol) to 3.2% (pain). The average annual changes in Medicaid
prescriptions were highly variable—from7.5% (OH) to 8.2% (IL). Average national
OPC among these drug markets have decreased an average of 20.1% per year com-
pared to a decrease of 4.8% among private insurers. CONCLUSIONS: Medicaid al-
ready represents a significant portion of prescription volume, and that patient access
is constantly increasingwithprecipitouslydecreasingOPC.With the impending rise in
Medicaid enrollment in 2014, prescription volumeswill increase further, representing
a great opportunity for the external management of Medicaid plans.
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ANALYSIS OF THE SIX PROTECTED MEDICATION CLASSES BASED ON PLAN
TYPE AND LOW INCOME SUBSIDY STATUS
Blackwell S, Waldron C, Evans M
Centers for Medicare & Medicaid Services (CMS), Baltimore, MD, USA
OBJECTIVES:The primary research questionwas to identify trends in cost of the six
protected medication classes in the Part D program based on plan type and low
income status between calendar years 2007 and 2008. The second research ques-
tion was to identify trends in gap phase and catastrophic phase entry.METHODS:
The primary data source was the prescription drug event data in the Chronic
Condition Warehouse (CCW) for 2007 and 2008. Data were inflation-adjusted.
Results are based on analysis of 100% data for Medicare beneficiaries in the
CCW. The six protected medication classes under study were anticonvul-
sants, antidepressants, antineoplastics, antipsychotics, antiretrovirals, and
immunosuppressants. RESULTS: Beneficiaries enrolled in PDPs had higher drug
costs per person across all drug classes for both years compared to those in MA-
PDs. LIS enrollees had higher drug costs per person for each year for the drug
classes compared to non-LIS enrolleeswith the exception of antineoplastics. These
findings were in the context of number of prescriptions filled per enrollee increas-
ing less than one percent between calendar years 2007 and 2008 for all drug classes.
Odds ratio point estimates between the two years for gap phase entry and cata-
strophic phase entry indicate that PDP and LIS enrollees were more likely to reach
the gap and catastrophic phases as compared to their counterparts (i.e., MA-PD and
non-LIS enrollees) for both calendar years. CONCLUSIONS: Findings suggest that
drug costs per person increased from 2007 to 2008. In general, the increase was
higher for MA-PD enrollees (compared to PDP enrollees) as well as for LIS enrollees
(compared to non-LIS enrollees). A higher likelihood of gap phase and catastrophic
phase entry existed for PDP enrollees (compared to MA-PD enrollees) and for LIS
enrollees (compared to non-LIS enrollees) for all classes.
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CANADIAN PUBLIC DRUG PROGRAM SPENDING ON SENIORS, 2002 TO 2008
Hunt J, Gaucher M
Canadian Institute for Health Information, Ottawa, ON, Canada
OBJECTIVES: Seniors are estimated to account for about 40% of all Canadian retail
spending on prescription drugs, and make up a significant proportion of public
drug program expenditures. This analysis examines the types of drugs accounting
for themajority of public drug programspending for seniors, and the distribution of
program spending across seniors. METHODS: This study examined claims for
1,039,642 seniors on public drug programs in six Canadian provinces (Alberta, Sas-
katchewan,Manitoba, NewBrunswick, Nova Scotia and Prince Edward Island) from
2002 to 2008, representing over 80% of the senior population in those provinces in
2008. Public drug program spending on seniors refers only to the portion of pre-
scription costs paid by the public drug program, including professional fees and
markup, where applicable. RESULTS: In 2008, the top 10 drug classes, in terms of
public drug program spending, accounted for almost half (48.3%) of all spending on
seniors in the six provinces. 3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase
inhibitors accounted for the highest proportion of drug program spending for se-
niors, while 4 of the top 10 classes were used to treat hypertension. Almost half
(45.5%) of public drug program spending was for a small group of seniors (14.7%),
where the drug programs paid $2,500 or more of their annual drug costs. Tumour
necrosis factor alpha inhibitorswere the fastest growingdrug class, in termsof spend-
ing, growing at an average annual rate of 58.4% between 2002 and 2008.
CONCLUSIONS: Findings showalmosthalf of drugprogramspending for seniors is on
a small number of drugs. This suggests that any cost saving initiatives that impact
spending on these drugs could have a significant impact on overall public drug pro-
gram spending.
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COMPLIANCE WITH TREATMENT GUIDELINE RECOMMENDATIONS: USE OF
OVER-THE-COUNTER MEDICATIONS IN PATIENTS RECEIVING
BISPHOSPHONATES, ANTIEPILEPTICS, OR CHRONIC OPIOIDS
Barnes KD, Heaton PC
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: This study determined the frequency of OTC medication use follow-
ing treatment guidelines, specifically the percentage of patient visits recorded in
the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Am-
bulatory Medical Care Survey outpatient department (NHAMCS) that included (1)
bisphosphonates with calcium, (2) divalproex or carbamazepine therapy with folic
acid, and (3) fentanyl or methadone therapy with a laxative. METHODS: A retro-
spective, observational study was conducted using NAMCS and NHAMCS data
from 2006-2008. Data for visits including bisphosphonates with calcium, dival-
proex or carbamazepine in women of childbearing age with folic acid, and metha-
done or fentanyl in adults over age 40 years with laxatives were collected. Descrip-
tive statistics and logistic regression were used to analyze weighted data to
produce national estimates. RESULTS: Calcium was used in 25.3% of visits with
bisphosphonate therapy; visits associated with antiepileptics and chronic opioids
had lower rates of supplementation, with 5.0% including folic acid and 3.7% includ-
ing laxatives. Visits by Asians (OR2.74;CI 1.42-5.27) and patients from the north-
east (OR1.57; CI 1.10-2.24) or midwest (OR1.65;CI 1.15-2.37) were more likely to
include calcium,while visits by patientswithMedicaid (OR0.48;CI 0.30-.0.78)were
least likely to include calcium. In visits with antiepileptics, Asian women (46.0%)
and women with private insurance (9.5%) were more likely to receive folic acid. In
visits that included chronic opioids, only 1.2% of patients age 40-49 years included
a laxativewhile 6.7% of visits by patients over 70 years included a laxative. Laxative
use was low in visits by African American patients (1.8%) and patients residing in a
zip code with 12.84% of the population holding a bachelor’s degree (1.9%).
CONCLUSIONS: Themajority of patients were not receiving OTC supplementation
vital to the treatment of osteoporosis, epilepsy, and chronic pain. Targeted inter-
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vention to improve treatment guideline adherence would increase compliance
with recommendations.
Health Care Use & Policy Studies – Equity and Access
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EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH
INSURANCE: THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA
Maceira D
CEDES, Buenos Aires, Argentina
OBJECTIVES: In Argentina, the public health system is deeply decentralized and
organized mainly at the provincial level. In this context, differences regarding
income distribution and access to health services require the creation of regulatory
devices and State intervention. One of the answers provided by the Buenos Aires
Health Ministry was the creation of Provincial Public Health Insurance. This pro-
gram included an innovative mechanism of human resources payment for the
public sector– a capitated system with the possibility to generate a plus over the
fixed salary- and aimed to reach the coverage of 2.4 million of citizens. The object
of this research is to analyze the performance of the strategy in terms of focaliza-
tion and development of preventive tasks associated to a higher quality at the
primary healthcare level.METHODS: A database of 1.7 million of consultations in
59 municipalities during the period 2004 to 2006 was analyzed, considering the
evolution of preventive and curative consultations. Logistic regression models
were implemented to determine the variables conditioning those tendencies.
RESULTS: The programwas appropriately focalized in poormunicipalities. Preven-
tive consultations increased 107% during the three-year period, and curative con-
sultations decreased by 56%. Preventive consultations were significantly associ-
atedwith young and female patients, as well as younger physicians. Also, poor and
populatedmunicipalities showed high associations with preventive consultations.
Differences between municipalities were relevant, showing significant associa-
tions on both signs. CONCLUSIONS: The insurance’s hiring and payment mecha-
nisms, result to be innovative and successful in the context of public health sub-
sector, conditioning the professionals to increase their efforts towards higher
quality preventive care. The strategymight be seen as one of the instruments with
the potential to enhance care quality and performance. Nevertheless, municipali-
ties show particular characteristics regarding their management and administra-
tive structures that affect the success of the program.
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CAN PRICING SCHEMES IMPROVE MARKET ACCESS FOR INNOVATIVE HIGH
PRICED DRUGS?
Anastasaki E, Colasante W, Imbeah-Ampiah R
PriceSpective Ltd., London, UK
OBJECTIVES: European payers are facing high levels of uncertainty about the value
of innovative drugs and their budget impact. These uncertainties are related to
both the drug’s actual usage such as dosing requirements as well as external fac-
tors such as patients’ clinical response and drug’s relative effectiveness. Over the
years, pricing schemes have been proposed to increase budget predictability. Due
to the varying perceptions of attractiveness, these schemes are not similarly ad-
opted across Europe. The research assessed the attractiveness of various schemes
as a way to reduce budget impact uncertainties and improve patient access to
innovative high priced drugs. METHODS: Both primary and secondary research
was conducted. The secondary research of published data, such as payers’ assess-
ments of pricing schemes and countries’ past policies allowed us to develop a
framework to understand the relative weights of the factors affecting payers’ un-
certainty regarding innovative-high priced drugs. The framework was then vali-
dated through qualitative primary research. RESULTS: The results revealed payers’
preference towards the cost per cycle proposition, because of its ease of implemen-
tation. Nevertheless, of the countries examined, only the UK and Italy were expe-
rienced with pricing schemes. Few others appeared to be relatively open to
schemes, sometimes at the local level and/or when more traditional approaches
are present.Most countrieswere very resistant to pricing schemes, primarily due to
the perceived complexity of schemes management and the transparency associ-
ated with it. Respondents’ opinions regarding pricing schemes also varied in terms
of the line of therapy they are targeted to. CONCLUSIONS: The heterogeneity of
Europemakes it difficult to have one scheme fit all. Schemes can reduce uncertain-
ties associated with therapy outcomes and budgetary expenditures; however pay-
ers are not willing to take additional risks associated with pricing schemes for
innovative high price drugs and prefer traditional straight discounts.
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REVIEW OF HIGHLY SPECIALIZED MEDICAL SERVICES IN KAZKAHSTAN
WITHIN AN INTRODUCTIN OF UNIFIED NATIONAL HEALTH SYSTEM
Yergaliyev K, Issayeva R, Umralin T
Ministry of Health of Republic of Kazakhstan, Astana, Kazakhstan
OBJECTIVES: As a consequence of the sweeping reforms in 2010 Kazakhstan has
introduced newly Unified National Health System (UNHS), which aims at improv-
ing the health of citizens through free choice of doctors andmedical organizations,
and introduction of new financial models and economic incentives for health care
providers, among others. Within UNHS reimbursement of highly specialized med-
ical services (HSMS) is based on increased tariffs. According to Law of Kazakhstan,
HSMS are services provided using new (high) health technologies. Objectives for
the paper were to review current condition of HSMS in the country, to identify
problems and to provide appropriate recommendations to meet needs of evolving
UNHS.METHODS: Retrospective analysis of health services provided by Secondary
care regional medical centers (Regional centers) (n848) and Republican level ter-
tiary care medical centers (Republican center) (n22) over 10 months in 2010, re-
view of regulatory documents related to HSMS. RESULTS: 6% of Regional centers
and 59% of Republican centers provide HSMS. Only 12% of case mix of Republican
center is HSMS. A list of HSMS technologies that is approved by Ministry of Health
mostly consists of surgery protocols (94%). There are no clear criteria to define
HSMS. Republican centers have transferred 37 high technologies to Regional
centers. CONCLUSIONS: Introduction of UNHS created a base for competitive en-
vironment in Kazakh Healthcare system. First time in a history, Regional centers
have started to provide HSMS and Republican centers report about significant de-
cline in a number of patients that need HSMS and reduction of waiting list. As a
result, an access of Kazakh population to HSMS has improved. These findings have
shown an urgent need for health technology assessment methodology and tools,
as it helps to define truly effective health technology and to manage scarce gov-
ernment budget for health services.
Health Care Use & Policy Studies – Formulary Development
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ANALYSIS OF PHARMACISTS’ INTERVENTIONS ON ELECTRONIC VERSUS
TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES
Gilligan A, Miller K, Mohney A, Montenegro C, Schwarz J, Warholak TL
University of Arizona, Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to: 1) measure the incidence of pre-
scription problems that require pharmacist intervention; 2) determine the types
and relative frequency of prescription conveyance which contain problems that
require pharmacist intervention; and 3) estimate the pharmacy personnel time and
related practice expenses for prescriptions requiring intervention.METHODS: This
prospective study utilized an adaptation of the medication therapy intervention
(MTI) data collection form. Data were collected at two chain grocery store pharma-
cies by directly observing pharmacists for 3weeks, during the hours of 9am to 6pm.
Information recorded with each intervention included the type of prescription,
medication in question, reasons for intervention, intervention outcome, and time
spent performing intervention. Chi square analysis was conducted to compare
percentage of intervention rates between prescription conveyances. Kruskal-Wal-
lis rank test was utilized to compare the time on task values for the interventions.
Poisson regressionwas used in order to determine if significant differences existed
among the total number of interventions per group. RESULTS: Pharmacists re-
viewed 1678 new prescriptions and intervened on 157 (9.4%) over a 13 day period. A
total of 12 hours and 11 minutes was required to perform all interventions for an
overall average of 4.79 (SD0.34) minutes per intervention. Percentage of interven-
tion rates between prescription conveyances was not statistically significant
(p0.21). The time on task values for the interventions were also not statistically
significant (p0.39). However, compared with handwritten interventions, e-pre-
scribing interventions occurred 1.57 times less (p0.0001), faxed interventions oc-
curred 1.52 times less (p0.0001), and verbal interventions occurred 2.05 times less
frequently (p0.001), on average. CONCLUSIONS: E-prescribing interventions oc-
curred less frequently comparedwith handwritten interventions, whichmay pres-
ent a potential benefit. Future efforts to develop and enhance e-prescribing are
needed to add measurable value to patient care.
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IMPACT OF PHARMACY AND MEDICAL PLAN INTEGRATION ON OVERALL
MEDICAL COSTS
Bunz TJ, Nguyen HV, Regine ML
CIGNA HealthCare, Bloomfield, CT, USA
OBJECTIVES: Studies published by Aetna and Health Partners have demonstrated
the value of integrated medical and pharmacy benefits in their populations. Com-
bined coverage provides the opportunity for coordinated patient outreach and
aligned policy decisions. The purpose of this analysis is to determine if integrated
benefits result in lower total medical costs when compared to plans that utilize a
carve-out pharmacy benefit.METHODS:A retrospectivematched cohort studywas
utilized in order to compare the total medical costs associated with customers in
integrated health plans with customers with a carve-out PBM. Individual custom-
ers were included if they were continuously enrolled for at least 12 months within
the same plan type, had a full set of demographic, risk, and clinical data, and were
between the ages of 18 and 65. The two groups were matched based on demo-
graphic, comorbidity, and employer characteristics. RESULTS: This analysis
matched 39,896 customers in 2007 (19,948 in each group) and 151,144 customers in
2008 (75,572 in each group) for the final analysis. Medical costs were $13.77 (p-value
0.067) and $11.39 (p-value 0.006) per customer permonth lower for customerswith an
integrated pharmacy benefit as compared to carve-out customers in 2007 and 2008
respectively. In 2007 and 2008 the bulk of the savings ($6 and $7 pcpm respectively)
were associated with lower utilization of outpatient services. CONCLUSIONS:When
controlling for demographic, clinical, and employment characteristics, there is a
significant savings associated with integrating medical and pharmacy benefits.
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DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT:
THE GOOD, THE BAD, AND THE FUTURE
Machado M1, Fonseca E2, Fonseca M3
1GlaxoSmithKline Brazil, Rio de Janeiro, Brazil, 2Federal University of São Paulo, São Paulo,
Brazil, 3Axia.Bio, São Paulo, Brazil
OBJECTIVES:Despite the premise of universal access supported by its Constitution,
the Brazilian healthcare system is subject to similar financing issues as in other
jurisdictions worldwide. A misunderstanding between Constitutional rights and
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